CorMedix Announces Positive Phase III Results for REZZAYO, Meeting Primary Endpoint for Fungal Prophylaxis
CRMD sits 22% above its 52-week low of $6.125.
Summary
CorMedix announced positive Phase III clinical trial results for REZZAYO, meeting its primary endpoint for prophylaxis of invasive fungal infections and opening a substantial new market opportunity.
Key Events · Product Development and Regulatory · CRMD
-
Positive Phase III Clinical Trial Results
CorMedix announced positive topline results from the global ReSPECT Phase III study for REZZAYO® (rezafungin for injection).
-
Primary Endpoint Met
The study met its primary endpoint, demonstrating non-inferiority versus standard antimicrobial regimen in fungal-free survival at Day 90 (60.7% for rezafungin vs. 59.0% for SAR).
-
Favorable Safety and Interaction Profile
REZZAYO was well tolerated with a safety profile comparable to standard regimens, showing favorable benefits for toxicity-related discontinuations and drug-drug interactions.
-
Significant Market Opportunity
The company estimates the potential US market opportunity for REZZAYO in prophylaxis exceeds $2 billion, supported by orphan drug exclusivity through 2035 and patent coverage through 2038.
Analysis · CRMD · Life Sciences
CorMedix has reported highly positive topline results from its Phase III ReSPECT trial for REZZAYO, demonstrating non-inferiority in fungal-free survival for prophylaxis of invasive fungal infections. This successful outcome significantly de-risks the drug's potential for an expanded indication, opening up an estimated US market opportunity exceeding $2 billion. The favorable safety profile and reduced drug-drug interactions further enhance REZZAYO's competitive positioning. This clinical milestone is crucial for CorMedix, building on its recent financial turnaround and providing a strong growth driver for future revenue, with an sNDA submission targeted for the second half of 2026.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRMD was trading at $7.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $581.9M. The 52-week trading range was $6.13 to $17.43. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.